EB1 is a MNK Kinase Inhibitor and Selectively Inhibits the Growth of Cancer Cells
MNKs (Mitogen-activated protein kinase interacting kinases) belong to the family of Ser/Thr kinases, and are classified as members of Ca2+/calmodulin-dependent kinases. MNKs have two different isoforms (MNK1 and MNK2) and play critical roles in the development of human malignancies. MNK1 and MNK2 execute a unique function in regulating eIF4E...
MPT0B014, a Tubulin Polymerization Inhibitor Induces Cancer Cell Apoptosis
Microtubules are polymers of microtubule proteins that form part of the cytoskeleton and provide structure and shape for eukaryotic cells. Specifically, Microtubules play an important role in many cellular processes. They participate in maintaining cellular structure and form the cytoskeleton together with microfilaments and intermediate filaments. Besides, Microtubes are...
MC0704 is a STAT3 Inhibitor for Triple-negative Breast Cancer Research
Breast cancer (BC) is one of the main causes of cancer-associated death in women. And, BC is high recurrence and/or metastatic potential. BC is typically categorized into respective subtypes based on the presence of representative receptors (the human epidermal growth factor receptor, estrogen receptor, and progesterone receptor). Hence, these...
Palbociclib is an Orally Active CDK4 and CDK6 Inhibitor for Cancer Research
Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose activity depends on a regulatory subunit-a cyclin. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa. What’s more, CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and...
BPDA2 is a Highly Selective and Competitive SHP2 Inhibitor
SH2-containing protein tyrosine phosphatase 2 (SHP2) is a carcinogenic phosphatase. Specifically, SHP2 participates in the downstream signal transmission of various RTK. So it is the shared signal node for analysis. The phosphatase activity of SHP2 is necessary for important cancer-related signaling pathways (such as RAS and PI3K). Besides, the...
Elacestrant (RAD1901) is an Orally Available Estrogen Receptor Degrader
Breast cancer is subdivided into categories based on the tumor receptor status. Specifically, whether the tumor expresses estrogen receptor (ER), progesterone receptor (PR), or Her2. And, with ER+ disease makes up the majority of patients in the breast cancer patient population. Although there are currently available drugs against ER-positive...
MS8815 is a EZH2 PROTAC Degrader for Targeting Triple-Negative Breast Cancer (TNBC)
Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of polycomb repressive complex 2 (PRC2). EZH2 drives oncogenesis not only in a canonical H3K27me3-dependent manner but also through non-canonical H3K27me3-independent functions. It exhibits overexpression in triple-negative breast cancer (TNBC). However, EZH2 catalytic inhibitors are ineffective in suppressing the...